Ionis Pharmaceuticals Inc.


Company Update (NASDAQ:IONS): Ionis Pharmaceuticals Inc Licenses First Oral Antisense Drug Acting Locally in the GI Tract to Janssen

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced that it has earned $10 millionfrom Janssen Biotech, Inc. (Janssen) upon licensing IONIS-JBI1-2.

Leerink Swann Slashes Price Target for Ionis Pharmaceuticals Inc (IONS); Here’s Why

On Wednesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) hosted an R&D day in NYC, where it framed the antisense/IONS vs RNAi debate particularly as it pertains to …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts